FLNA · XBRL financial data

Filana Therapeutics financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (FLNA's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Research and development	—	24,813	68,032	89,423	69,637	26,590
General and administrative	3,739	8,055	11,988	16,534	71,809	68,800
Total operating expenses	6,446	32,868	80,020	105,957	141,446	95,390
Operating income (loss)	(6,446)	(32,868)	(80,020)	(105,957)	(141,446)	(95,390)
Other income (expense)	—	434	997	907	411	(203)
Income tax expense (benefit)	—	—	—	—	0	0
Net income (loss)	(6,334)	(32,385)	(76,246)	(97,217)	(24,342)	(90,973)
Earnings per share, basic USD per share	—	(0.82)	(1.90)	(2.32)	(0.53)	(1.88)
Earnings per share, diluted USD per share	—	—	(1.90)	(2.32)	(1.46)	(1.88)
Weighted average shares, basic thousands of shares	—	39,405	40,202	41,932	46,329	48,297
Weighted average shares, diluted thousands of shares	—	—	40,202	41,932	46,604	48,297

Fiscal years (FLNA's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	93,506	233,437	201,015	121,136	128,574	95,502
Prepaid and other current assets	488	11,045	10,211	8,497	7,958	2,207
Total current assets	93,994	244,482	211,226	129,633	136,532	97,709
Property and equipment, net	11	20,616	22,864	21,854	20,964	20,646
Right-of-use asset	295	210	122	0	—	—
Total assets	94,300	266,782	234,834	151,663	157,533	118,355
Accounts payable	911	7,126	4,017	—	—	—
Accrued liabilities	719	2,803	2,280	—	—	—
Total current liabilities	1,865	12,534	7,063	14,195	11,750	43,834
Lease liability, non-current	235	139	35	0	—	—
Total liabilities	2,100	12,867	7,295	14,195	11,829	43,952
Accumulated deficit	(174,921)	(207,306)	(283,552)	(380,769)	(405,111)	(496,084)
Total stockholders' equity	92,200	253,915	227,539	137,468	145,704	74,403
Total liabilities and equity	94,300	266,782	234,834	151,663	157,533	118,355
Common shares outstanding (cover page) thousands of shares	39,898	40,017	41,736	43,225	48,308	48,308

Fiscal years (FLNA's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(6,334)	(32,385)	(76,246)	(97,217)	(24,342)	(90,973)
Stock-based compensation	988	1,759	2,066	4,586	16,291	19,582
Depreciation and amortization	22	—	—	—	—	—
Net cash from operating activities	(5,382)	(30,196)	(77,514)	(82,025)	(116,929)	(32,252)
Purchases of property and equipment	—	22,214	2,712	414	103	581
Net cash from investing activities	360	(22,214)	(2,712)	(414)	(103)	(581)
Proceeds from issuing common stock	70,251	189,825	47,329	0	0	—
Net cash from financing activities	75,447	192,341	47,804	2,560	124,470	(239)

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Filana Therapeutics	46,990	not reported	(6,094)*	50.3M	7.5 quarters	Q3 FY26 10-QSep 30, 2026
Anixa Biosciences	1,398	not reported	(1,770)*	34.8M	6.8 quarters	Q3 FY26 10-QJul 31, 2026
GENELUX	9,184	not reported	(6,444)*	45.2M	2.9 quarters	Q2 FY26 10-QJun 30, 2026
Entera Bio	11,309	0	(3,464)*	173.1M	3.3 quarters	Q2 FY26 10-QJun 30, 2026
Immunic	155,098	not reported	(30,998)*	13.6M	5.0 quarters	Q2 FY26 10-QJun 30, 2026
Coherus Oncology	82,923	not reported	(62,090)*	154.5M	1.7 quarters	Q2 FY26 10-QJun 30, 2026
Elicio Therapeutics	30,900	not reported	(10,364)*	28.3M	3.1 quarters	Q3 FY26 10-QSep 30, 2026
Larimar Therapeutics	92,687	not reported	(44,030)*	103.9M	3.5 quarters	Q2 FY26 10-QJun 30, 2026
DiaMedica Therapeutics	5,129	not reported	(8,114)*	53.9M	5.4 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.

Data on this page was fetched Nov 6, 2026, 2:18 PM ET. The filing on SEC.gov is the record.